JAZZ PHARMACEUTICALS PLC (JAZZ)

IE00B4Q5ZN47 - Common Stock

128.45  +0.03 (+0.02%)

After market: 128.45 0 (0%)

News Image
2 days ago - Seeking Alpha

Jazz Pharmaceuticals names Philip Johnson as CFO (NASDAQ:JAZZ)

Jazz Pharmaceuticals announces Philip Johnson as new CFO, effective March 1, 2024.

News Image
2 days ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice...

News Image
3 days ago - InvestorPlace

3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition

Don’t miss out, as the following cannabis stocks are severely undervalued and are set to increase sales and make huge profits in 2024.

News Image
3 days ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: TD...

News Image
9 days ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on...

News Image
16 days ago - InvestorPlace

3 Biotech Stocks to Buy on the Dip: February 2024

Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

News Image
16 days ago - Seeking Alpha

Jazz Pharmaceuticals to buy global rights to KRAS inhibitor program (NASDAQ:JAZZ)

Jazz Pharmaceuticals to acquire Redx's KRAS inhibitor program, expanding its oncology pipeline and aiming to improve treatment options for cancer patients.

News Image
16 days ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement...

News Image
17 days ago - InvestorPlace

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

News Image
20 days ago - The Motley Fool

4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The growth-fueled Nasdaq Composite remains nearly 6% below its all-time high, which means amazing deals can still be found.

News Image
23 days ago - InvestorPlace

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024

Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out.

News Image
a month ago - The Motley Fool

2 Incredible Growth Stocks That Are Screaming Buys for 2024

These healthcare businesses are compelling buys for very different reasons.

News Image
a month ago - The Motley Fool

4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found.

News Image
2 months ago - InvestorPlace

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World

If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now.

News Image
2 months ago - Seeking Alpha

Jazz Pharma PTSD mid-stage trial fails to meet main goal (NASDAQ:JAZZ)

Jazz Pharmaceuticals (JAZZ) on Thursday said a mid-stage trial of JZP150 for the treatment of PTSD failed to meet the main goal of the study. Read more here.

News Image
2 months ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an...

News Image
2 months ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan...

News Image
2 months ago - The Motley Fool

3 No-Brainer Stocks to Buy With $500 Right Now

You don't need a mountain of cash to build wealth on Wall Street.

News Image
3 months ago - Seeking Alpha

Jazz presents encouraging Phase 2 data for breast cancer treatment (JAZZ)

Jazz Pharmaceuticals presented positive Phase 2 data for zanidatamab in the treatment of metastatic HER2+/HR+ breast cancer at a medical meeting. Read more here.

News Image
3 months ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted...

News Image
3 months ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will...

News Image
3 months ago - Jazz Pharmaceuticals plc

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio...

News Image
3 months ago - InvestorPlace

3 Top-Rated Biotech Stocks That Analysts Are Loving Now

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

News Image
3 months ago - Seeking Alpha

UBS lowers Jazz to neutral, cites potential competition from Avadel drug (NASDAQ:JAZZ)

UBS lowered its rating of Jazz Pharmaceuticals (JAZZ) to neutral, citing potential competition from Avadel's (AVDL) Lumryz sleep drug. Read more here.

News Image
3 months ago - The Motley Fool

3 Biotech Stocks That Could Be Millionaire Makers

Many biotech stocks offer exciting long-term growth prospects.

News Image
3 months ago - The Motley Fool

3 No-Brainer Stocks to Buy With $200 Right Now

A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.

News Image
3 months ago - Seeking Alpha

Jazz Pharma enters collaboration to develop neurological drugs (NASDAQ:JAZZ)

Jazz Pharmaceuticals partners with Autifony Therapeutics to develop drug candidates for neurological disorders, with milestone payments up to $770.5M.